343 related articles for article (PubMed ID: 7682149)
1. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.
Akakura K; Bruchovsky N; Goldenberg SL; Rennie PS; Buckley AR; Sullivan LD
Cancer; 1993 May; 71(9):2782-90. PubMed ID: 7682149
[TBL] [Abstract][Full Text] [Related]
2. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.
Goldenberg SL; Bruchovsky N; Gleave ME; Sullivan LD; Akakura K
Urology; 1995 May; 45(5):839-44; discussion 844-5. PubMed ID: 7538246
[TBL] [Abstract][Full Text] [Related]
3. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
[TBL] [Abstract][Full Text] [Related]
4. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
5. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
6. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Holub S; Dürer A; Andert S; Haberl I; Theyer U; Hamilton G
Br J Cancer; 1997; 75(10):1515-8. PubMed ID: 9166947
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
8. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
9. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
Pedraza R; Kwart AM
Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
[TBL] [Abstract][Full Text] [Related]
10. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Leibowitz RL; Tucker SJ
Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
[TBL] [Abstract][Full Text] [Related]
11. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
12. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
13. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
14. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
Rabbani F; Goldenberg SL; Klotz LH
J Urol; 1998 Mar; 159(3):925-8. PubMed ID: 9474184
[TBL] [Abstract][Full Text] [Related]
15. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
16. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
Sato N; Gleave ME; Bruchovsky N; Rennie PS; Goldenberg SL; Lange PH; Sullivan LD
J Steroid Biochem Mol Biol; 1996 May; 58(2):139-46. PubMed ID: 8809195
[TBL] [Abstract][Full Text] [Related]
18. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
Nejat RJ; Rashid HH; Bagiella E; Katz AE; Benson MC
J Urol; 2000 Dec; 164(6):1891-4. PubMed ID: 11061874
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]